Rostock International Parkinson's Disease Study (ROPAD)
ROPAD is an international, multicenter, epidemiological, observational study with the goal to investigate the genetic background of Parkinson’s patients. This study is closely linked to the scientific follow-up (LIPAD) study with the University of Lübeck.
The Rostock International Parkinson's Disease Study (ROPAD) is a global observational study focusing on the role of genetics in Parkinson's disease (PD). The major goal of the study is to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment. Throughout this study, up to 20,000 participants from around the world, made up of PD patients and individuals at high risk of developing PD, will be tested over a period of two years – with the overall aim of identifying 1,500 LRRK2-positive participants.
PD can be caused by several factors, including environmental factors, genetics, and aging. In recent years, a growing number of PD related genes have been described – including LRRK2 and GBA. Thus, the identification of new genes and mutations associated with PD will not only improve our understanding of the underlying molecular mechanisms, but may also lead to the development of new drugs and treatments.
In the case of a LRRK2 mutation, the participant may be offered participation in future clinical studies.
Design: International, epidemiological, observational, non-interventional study
Study population: PD patients and high-risk populations
Number of participants: 20,000 participants
First participant in: April 2019
Last participant in: December 2023
Objectives: Epidemiological analysis of the prevalence of LRRK2-positive patients and of patients with PD-related gene alterations (other than LRRK2 gene) in a cohort of PD patients
Identification of 1,500 LRRK2 positive patients and of ~500 patients with monogenic PD (other than LRRK2)
Find out how you can participate: ClinicalTrials.gov
ROPAD is a global study currently being conducted in the United States, Brazil, Europe, and Israel. Participating countries and the geographic distribution facilitate a broad genetic and ethnic background that mirrors the global population.
- One of the most common neurodegenerative disorders worldwide: Approximately 1% of individuals over 60 years are affected
- Likelihood of developing PD increases with age and is more frequent in males
- Both genetic and environmental factors may contribute to PD
- Characterized by pathological toxic protein deposits in neurons, leading to a deficiency of neurotransmitters such as dopamine
- Clinical symptoms include tremors, muscle rigidity, postural instability, and gait abnormalities
Who can participate in the ROPAD Study?
The participation in the study is available for individuals older than 18 years of age and who fulfill the following criteria:
- Informed consent is provided.
- Clinically diagnosed with PD
- First- and second-degree family memeber of a Positive LRRK2 participant enrolled in the ROPAD Study
- At high risk due to ethnicity/family history.
What should I expect from participating in the ROPAD Study?
As a participant in the ROPAD Study, you will be asked to provide a signed consent form, a small blood sample, which will be applied to a CentoCard®, and a short clinical history, as well as to perform a neurological exam.
The CentoCard® will be sent and analyzed in CENTOGENE’s laboratory for mutations that may be relevant to PD.
If you have agreed to being informed about the genetic testing results, your doctor will share the medical report with you.
After receiving your genetic test results, your doctor can provide further consultation or you/your doctor can request a free genetic counseling via this email: genetic(dot)counseling(at)centogene(dot)com. During counseling, you will have the opportunity to gain a deeper understanding of your medical results and the impact of the findings on your family.
CENTOGENE’s partners from the University of Lübeck (Prof. Christine Klein, MD and Prof. Meike Kasten, MD) will contribute to further clinical and genetic assessments via the program, “LRRK2 International Parkinson’s Disease Project (LIPAD).” All ROPAD-enrolled participants with any genetic mutation can be enrolled in the LIPAD study. Additionally, the University of Lübeck aims to collect 500 healthy controls (no LRRK2 mutation and no PD manifestation), who are recruited from the families of unaffected mutation carrier.
For the idiopathic PD patients, the University of Lübeck aims to collect 1,500 PD patients without a mutation in LRRK2, who are recruited from those who have tested negative.
CENTOGENE's pharmaceutical partner DENALI Therapeutics Inc. (California, U.S.) develops investigational therapies for the treatment of neurodegenerative diseases, as well as others. Any participant testing positive for LRRK2 mutations that meets eligibility criteria may be offered participation in one of their future clinical studies.